The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent on two cancer drugs the company is developing, including its lead drug candidate, according to the company.

Madison, WI-based Cellectar (NASDAQ: CLRB) says the patent covers the use of its lead drug candidate, CLR 131, for treating several forms of malignant solid tumors. They include adrenal, breast, colon, liver, lung, ovarian, and prostate cancers, according to a press release. (To date, Cellectar’s main focus has been developing the drug as a treatment for blood cancers.) The patent also covers CLR 125, which Cellectar is developing to treat micro-metastatic cancer, or tiny, newly formed tumors. Both drugs are so-called radiotherapeutics, which combine a cancer-killing isotope with a targeting molecule designed to ferry the isotope to the cancer cells and spare healthy cells. Read the full story here.